{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:25:08Z","timestamp":1770690308668,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Am Coll Clin Pharm"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic inertia (TI) in type 2 diabetes mellitus (T2DM) is defined as the lack of timely adjustment to therapy when a patient's treatment goals are not met. Failure to initiate or intensify evidence\u2010based therapies for T2DM increases the risk of micro and macrovascular disease complications. There are limited data regarding clinicians' (nurse practitioners and pharmacists) perceptions of TI and patient\u2010perceived barriers to therapeutic progress in T2DM. A better understanding of perceptions of TI might assist in identifying targeted interventions to limit its occurrence. The objective of this study was to determine perceived factors that contribute to TI in patients with T2DM from a primary care clinician perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multi\u2010centered prospective qualitative study. Purposive sampling was used. Primary care clinicians, licensed in the state of Michigan and treating patients with T2DM, were assessed on their attitudes and beliefs toward TI in the treatment of T2DM. Participant interviews were conducted by one investigator, and responses were independently reviewed by two separate investigators. Data were coded, organized, and analyzed using Dedoose software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen participants completed the study. Clinicians in the study were predominately pharmacists (57.1%) and female (92.9%) and the majority had more than 10\u2009years of practice experience (57.1%). Major themes identified to help overcome TI were the importance of patient education, empathy toward the patient, and team collaboration. Therapeutic barriers identified by clinicians included cost, clinician\/clinic time, and patient accountability.<\/jats:p>\n                    <jats:p>Several perceived facilitators and barriers to TI in the management of T2DM were identified. Clinicians described a team\u2010based approach with clearly delineated and complementary roles between clinicians to support patient care and minimize TI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TI remains a persistent problem in clinical practice. Several opportunities exist to reduce TI in patients with T2DM, which include a multidisciplinary approach to care and improved access to medications and services (transportation, nutrition education, etc.).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jac5.70146","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T09:26:51Z","timestamp":1763976411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinician Perceptions of Therapeutic Inertia in Type 2 Diabetes Mellitus: A Qualitative Study"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2658-8247","authenticated-orcid":false,"given":"Melissa","family":"Lipari","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"},{"name":"Henry Ford St. John Hospital  Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-9318","authenticated-orcid":false,"given":"Candice L.","family":"Garwood","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"},{"name":"DMC Harper University Hospital  Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7951-8790","authenticated-orcid":false,"given":"Helen","family":"Berlie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"},{"name":"Health Centers Detroit Medical Group  Detroit Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-9657","authenticated-orcid":false,"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Centers for Disease Control \u201cNational Diabetes Statistics Report \u201daccessed June 30 2025 https:\/\/www.cdc.gov\/diabetes\/php\/data\u2010research\/index.html."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010024\u201001530\u20109"},{"key":"e_1_2_10_4_1","unstructured":"American Diabetes Association \u201cTherapeutic Inertia \u201daccessed June 30 2025 https:\/\/professional.diabetes.org\/professional\u2010development\/overcoming\u2010therapeutic\u2010inertia."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14455"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.06.011"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110888"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-9-200111060-00012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12592"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-015-0221-1"},{"key":"e_1_2_10_11_1","volume-title":"Risk Communication: A Mental Models Approach","author":"Morgan M.","year":"2002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X16639015"},{"key":"e_1_2_10_14_1","volume-title":"Qualitative Data Analysis: A Methods Sourcebook","author":"Miles M. B.","year":"2014"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211023492"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9975"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.320"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2024.105550"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618\u2010023\u201002259\u20101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds22-0084"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14985"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0019"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hsc.12932"}],"container-title":["JACCP:  JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jac5.70146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jac5.70146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jac5.70146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:47:36Z","timestamp":1770626856000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/jac5.70146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jac5.70146"],"URL":"https:\/\/doi.org\/10.1002\/jac5.70146","archive":["Portico"],"relation":{},"ISSN":["2574-9870","2574-9870"],"issn-type":[{"value":"2574-9870","type":"print"},{"value":"2574-9870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"2025-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70146"}}